Novartis heart drug cuts Lp(a) 78% but fails to prevent cardiovascular events
AI Summary- Novartis’ pelacarsen failed to reduce cardiovascular events despite lowering Lp(a).
- 78% was the reduction in Lp(a) after monthly pelacarsen treatment.
- Novo Nordisk’s ziltivekimab also failed to reduce major cardiovascular events.